Onyx Biotec share price
NSE: ONYXPharmaceuticals & Biotechnology
Onyx Biotec Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2024 · Issue price ₹61
Last close ₹36.00down ₹0.50 (1.37%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹36.50.
28 Oct: open ₹36.00, high ₹36.00, low ₹36.00
52-week range of traded prices to 28 Oct 2026
₹24.20Low, 22 May 2026₹49.65High, 5 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹65 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.18
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −0.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.27
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,000100.0% delivered
Results
Standalone; ₹ crore.Onyx Biotec half-yearly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +12.1%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −104.3%
Half year to Mar 2026, against the half year before
- RevenueRevenue. The pill is the change in revenue against the half year before: this period's figure divided by that one's, less one, in per cent.
- ₹35 Crup 0.87%
- Net profitNet profit. Under it, net profit in the half year before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- ₹0.69 CrHalf year to Sep 2025: −₹0.90 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 2.0%
Revenue by half year
Peak revenue ₹35 Cr, half year to Mar 2026; lowest ₹30 Cr, half year to Sep 2024
Net profit by half year, a loss in red
- Net profit
- Loss
Back to profit in the half year to Mar 2026, ₹0.69 CrA loss in 1 of the 4 half years shown
| ₹ crore | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 30.1 | 31.8 | 34.6 | 34.9 |
| Net profit | 3.0 | 2.0 | −0.9 | 0.7 |
| Net margin | 9.9% | 6.2% | −2.6% | 2.0% |
Standalone. The 4 half years from Sep 2024, the first on record. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹69 Crup 12.14%
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹0.21 CrYear to Mar 2025: ₹4.95 Cr
- Net margin
- −0.3%
Revenue by year
Peak revenue ₹69 Cr, year to Mar 2026; lowest ₹62 Cr, year to Mar 2025
Net profit by year, a loss in red
- Net profit
- Loss
A loss in the year to Mar 2026, −₹0.21 Cr
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue | 62.0 | 69.5 |
| Net profit | 5.0 | −0.2 |
| Net margin | 8.0% | −0.3% |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, manufacture and sale distribution of generic and proprietary pharmaceutical products, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Dividend yield is not shown: no dividend in the years on record.Onyx Biotec PE ratio and valuation
Price to book
At or below today's level on 38% of 220 trading days over the last year.
LowestHighest
Its median1.22Industry median2.99
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −41.4% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Onyx Biotec insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Onyx Biotec competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Onyx Biotec in market cap.Healthcare companies
Onyx Biotec is not on the chart: it has no P/E today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Source Natural Foods & Herbal SupplSOURCENTRL | 73 | 19.36 | 2.82 | +63.1% | +20.6% | 15.6% | 16.7% | 0.00% |
 Sunil HealthcareSUNLOC | 70 | 19.55 | 1.00 | −0.6% | +1,851.4% | 5.2% | 4.9% | 0.00% |
 Vineet LaboratoriesVINEETLAB | 69 | 17.38 | 1.52 | +6.4% | – | 13.2% | 8.8% | 0.00% |
 Shelter PharmaSHELTER | 69 | 7.59 | 0.89 | +44.4% | +24.7% | 15.1% | – | 0.00% |
 Rekvina LaboratoriesVINRKLB | 64 | – | – | – | – | – | −139.0% | 0.00% |
 Zenith DrugsZENITHDRUG | 63 | 16.09 | 0.87 | +28.4% | −44.9% | 5.5% | – | 0.00% |
 PhaarmasiaPHRMASI | 57 | 3.21 | 2.56 | +111.8% | – | 114.5% | 7.1% | 0.00% |
 Vivimed LabsVIVIMEDLAB | 48 | – | – | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Onyx Biotec announcements
Oct 2026
14 Oct · Public Announcement-Open Offer
7 Oct · Committee Meeting Updates
7 Oct · Updates
Sep 2026
28 Sep · Meeting
Onyx Biotec share price by year
Each calendar year to 2025.Onyx Biotec share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 40.80 | −54.5% | 94.85 | 30.80 |
| 2024 | 89.60 | – | 89.60 | 53.35 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2024 is from its first session, 22 Nov 2024.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 36.50 | 36.50 | 36.50 | 36.50 | 36.50 | 2,000 | 100.0% |
| 26 Oct 2026 | 37.90 | 37.90 | 35.25 | 35.25 | 36.13 | 10,000 | 100.0% |
| 23 Oct 2026 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 4,000 | 100.0% |
| 22 Oct 2026 | 38.85 | 38.85 | 37.00 | 37.00 | 37.37 | 10,000 | 100.0% |
| 21 Oct 2026 | 37.25 | 37.25 | 37.00 | 37.00 | 37.12 | 4,000 | 100.0% |
| 19 Oct 2026 | 37.25 | 37.25 | 37.25 | 37.25 | 37.25 | 2,000 | 100.0% |
| 16 Oct 2026 | 37.25 | 37.25 | 37.25 | 37.25 | 37.25 | 2,000 | 100.0% |
| 15 Oct 2026 | 38.00 | 39.00 | 37.05 | 37.05 | 38.35 | 24,000 | 100.0% |
| 14 Oct 2026 | 37.50 | 37.50 | 37.50 | 37.50 | 37.50 | 2,000 | 100.0% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- ONYX
- ISIN
- INE0WVU01018
- Industry
- Pharmaceuticals & Biotechnology